1 Min Read
* ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION IN U.S. FOR LAROTRECTINIB FOR TREATMENT OF TRK FUSION CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.